In January 2023 U.S. Food and Drug Administration (FDA) approved a new treatment option for Alzheimer’s disease called Leqembi (lecanemab-irmb). The FDA accelerated its approval of the medication citing that the category of medications “represents an important advancement in the ongoing fight to effectively treat Alzheimer’s disease”.

Study results showed that lecanemab produced a clear yet modest clinical benefit for people in the early stages of Alzheimer’s. The medication slowed the rate of cognitive decline over 18 months and reduced the levels of brain amyloid when compared to placebo. Learn more in this article from the NIH National Institute on Aging (NIA).